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Abstract
Only a subset of patients will typically respond to any given prescribed drug. The time it takes clinicians to declare a
treatment ineffective leaves the patient in an impaired state and at unnecessary risk for adverse drug effects. Thus,
diagnostic tests robustly predicting the most effective and safe medication for each patient prior to starting
pharmacotherapy would have tremendous clinical value. In this article, we evaluated the use of genetic markers to
estimate ancestry as a predictive component of such diagnostic tests. We first estimated each patient’s unique mosaic of
ancestral backgrounds using genome-wide SNP data collected in the Clinical Antipsychotic Trials of Intervention
Effectiveness (CATIE) (n = 765) and the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) (n = 1892). Next,
we performed multiple regression analyses to estimate the predictive power of these ancestral dimensions. For 136/89
treatment-outcome combinations tested in CATIE/STAR*D, results indicated 1.67/1.84 times higher median test statistics
than expected under the null hypothesis assuming no predictive power (p,0.01, both samples). Thus, ancestry showed
robust and pervasive correlations with drug efficacy and side effects in both CATIE and STAR*D. Comparison of the marginal
predictive power of MDS ancestral dimensions and self-reported race indicated significant improvements to model fit with
the inclusion of MDS dimensions, but mixed evidence for self-reported race. Knowledge of each patient’s unique mosaic of
ancestral backgrounds provides a potent immediate starting point for developing algorithms identifying the most effective
and safe medication for a wide variety of drug-treatment response combinations. As relatively few new psychiatric drugs are
currently under development, such personalized medicine offers a promising approach toward optimizing pharmacother-
apy for psychiatric conditions.
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Introduction
It is well-known that only a subset of patients will respond to any
given prescribed drug [1]. The time it takes a clinician to declare a
treatment ineffective leaves the patient in an impaired state and at
unnecessary risk for adverse drug effects. Furthermore, drug
nonresponse reduces the likelihood of compliance and adherence
to future treatments [2]. Therefore, diagnostic tests capable of
identifying the most effective and safe medication for each patient
prior to initiating pharmacotherapy would have tremendous
clinical value [3,4]. Predicting drug nonresponse has, however,
proven to be difficult. These challenges have led to a proliferation
of pharmacogenetics research in the last decade. This research has
traditionally focused on pharmacodynamic and pharmacokinetic
candidate genes that encode drug targets or are involved in the
metabolism of the drug itself. More recently, genome-wide
association studies (GWAS) systematically screening markers
across the whole genome for association with drug response have
been added as a tool to identify relevant genetic variants [5].
However, before these genetic markers can be used in the clinic,
they will need to be evaluated more extensively through replicated
association and functional studies.
In the absence of firmly established panels of genetic markers
predicting the effects of specific drugs, it is sensible to search for
proxy variables robustly capturing relevant genetic differences
between individual patients. These proxies could serve as interim
components in the development of predictive algorithms for
individualizing pharmacotherapy. Based on observations of
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variability in drug-response between populations [6,7,8], we
hypothesize that ancestry information could be one such proxy.
To evaluate this hypothesis we used clinical and genetic
information from the two largest psychiatric clinical trials to test
therapy efficacy conducted in the United States: the Clinical
Antipsychotic Trials of Intervention Effectiveness (CATIE) [9]
(ClinicalTrials.gov Identifier: NCT00014001) and the Sequenced
Treatment Alternatives to Relieve Depression (STAR*D) [10]
(ClinicalTrials.gov Identifier: NCT00369746). Ancestral dimen-
sions were derived from genome-wide arrays including differences
across hundreds of thousands of single-nucleotide polymorphisms
(SNPs).
Methods
For both the CATIE and STAR*D studies, Supporting
Information S1 provides detailed information about the subjects
and study design, assessment instruments, estimation of treatment
effects, genotyping and estimation of ancestral dimensions. We
restrict ourselves to a short description here.
The CATIE study participants were recruited from 57 clinical
settings around the United States [9,11]. The Structured Clinical
Interview for DSM-IV was used to establish schizophrenia
diagnosis. The study consisted of a baseline, three phases and a
follow up. Patients were typically switched to another drug because
of a lack of efficacy or adverse effects. The STAR*D study is a
prospective, randomized clinical trial of outpatients with non-
psychotic major depressive disorder [10,12]. The Structured
Clinical Interview for DSM-IV was used to establish non-psychotic
major depressive disorder diagnosis. Sample collection involved 41
clinical sites across the United States. The full clinical trial study
sample includes 4,000 adults from both primary and specialty care
practices who had shown neither inadequate response nor
intolerance to any of the protocol treatments. The study consisted
of four phases. In the first phase all patients started with
citalopram. Different medications or medication combinations
for treatment resistant subjects were administered in each
subsequent phase.
Table 1 shows, for the main drug and outcome measures in
CATIE and STAR*D, the number of subjects assessed and the
mean number of observations across the entire trial. For clozapine
in CATIE, the sample sizes (,50) were much more modest than
the other drugs, for which there were on average 218 subjects per
drug-outcome combination with 3.6 assessments for each subject.
Citalopram in STAR*D had much higher sample sizes (1870) and
number of assessments (4.6) than the other antidepressants, which
had an average of 127 subjects per drug-outcome combination
with 3.8 assessments per subject.
In CATIE, 665,439 SNPs were genotyped using the Affymetrix
500 K chipset (Santa Clara, CA, USA) and a custom 164 K chip
created by Perlegen (Mountain View, CA, USA). After quality
control, genotypes for 492,900 SNPs from 738 individuals
remained for investigating ancestral background dimensions
[13]. In STAR*D a total of 969 subjects were genotyped at
Affymetrix, Inc. (South San Francisco) on the Human Mapping
500 K Array Set and another 979 samples were genotyped using
the Affymetrix Genome-Wide Human SNP Array 5.0. The two
groups were balanced by ethnic grouping, gender and proportions
of responders and non-responders. Twelve samples were geno-
typed on both the 500 K and 5.0 Arrays, with a .99%
concordance across these platforms [14]. After QC, 430,198
SNPs remained for use in the current analysis of ancestral
background dimensions.
To estimate ancestral background dimensions, we used the
multi-dimensional scaling (MDS) approach implemented in
PLINK [15], which has been demonstrated to be essentially
equivalent to the principal component method implemented in
EigenSoft [16]. Input data for the MDS approach were the
genome-wide average proportion of alleles shared identical by
state between any two individuals. The first ancestral dimension
captures the maximal variance in the genetic similarity; the second
dimension must be orthogonal to the first and captures the
maximum amount of residual genetic similarity; and so on. The
first five dimensions appeared to capture the vast majority of
ancestral variation in the CATIE and STAR*D samples and they
were used in the current analysis. The same number of dimensions
used here have been used in previous analyses of CATIE and
STAR*D [17,18,19,20,21,22,23,24].
One important, often neglected, issue in genomic studies using
genotype array-based estimates of ancestral background dimen-
sions (i.e., population structure) is the fact that various technical
genotyping artifacts can give rise to artifactual variance in array
data, which may in turn be captured as spurious ancestral
dimensions. These technical genotyping artifacts have the
potential to cause false positive associations if they are correlated
with the phenotypic outcome. Thus, for instance, in a case-control
study where cases and controls were genotyped in separate runs,
without rigorous QC for potential batch and plate effects, there
would be a serious risk that observed association between case-
control status and ‘‘ancestral dimensions’’ would actually be driven
by genotyping artifacts.
However, in the current study there are multiple sources of
evidence precluding the possibility of false positives due to
genotyping artifacts. The strongest evidence comes from the fact
that correlations between any genotyping artifacts and treatment
response are virtually impossible here. This is because in STAR*D
each array was, ‘‘balanced by ethnic grouping, sex, and
proportions of responders and nonresponders’’ [25]. For CATIE,
among the schizophrenia cases examined here, batch and plating
was randomized with no knowledge of treatment response status
[13]. Thus, correlations between batch (or plate) effects and
treatment response are explicitly impossible due to careful design
in STAR*D, and highly unlikely CATIE, as they would entail a
significant association between treatment response and a random
variable with no correlated signal (randomized plating and batch
assignment). These array randomization/balancing procedures
also essentially eliminate the possibility of correlation between
treatment response and other array-based artifacts, including
systematic subject differences in call rate and proportion of allelic
heterozygosity.
As an added precaution, however, both studies were QC’ed for
heterozygosity and call rate per subject (along with numerous
other rigorous QC procedures described in the original studies and
their supplemental materials [13,25]). Thus, in the post-QC data
analyzed here, call rates for all subjects were stringently high
(,.99.2) and all heterozygosity rates fell within 63 SD of the
mean, the threshold proposed in standard GWAS QC guidelines
[26]. Thus, due to balanced/randomized batch and plating and
rigorous QC, the risk of systematic genotype errors causing false
positives is effectively eliminated. However, it remains possible that
nonsystematic (i.e., uncorrelated with treatment response) geno-
typing errors may have eluded QC procedures and, thus,
contribute to the variance of the ancestral dimensions. However,
in this worst case scenario, artifactual variance would produce
noise in the ancestral dimensions, increasing the risk of false
negative associations. Thus, results of the current analysis may be
considered conservative.
Pharmacogenomics and Ancestral Background
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We previously developed a systematic method to estimate
treatment effects [27]. Our method uses mixed models to first
estimate the optimal functional form of over-time drug response,
then screens many possible covariates to select those that improve
the precision of the treatment effect estimates, and finally
generates individual treatment effect estimates based on the best
fitting model using best linear unbiased predictors (BLUPs) [28].
As our approach condenses all information collected during the
trials in an optimal, empirical fashion, it results in more precise
estimates than traditional approaches (e.g., subtracting pre- from
post-treatment observations) that estimate treatment effects using
only two assessments. We have successfully applied this method in
several genome-wide association studies performed on CATIE and
STAR*D samples [17,18,19,20,21,22,23,29].
After estimating MDS dimensions and treatment effects, we
performed multiple regressions to evaluate the association of MDS
dimensions and/or self-reported ethnicity with each drug-outcome
treatment response combination. These analyses were conducted
to investigate two specific issues. First, we considered whether
genotype-based ancestry has consistent, significant prognostic
power in predicting psychiatric drug response, and if so, how
strong is this predictive power. Second, we examined whether
genotype-based ancestry significantly improved prediction of
psychiatric drug response over and above the predictive power of
self-reported ethnicity.
In investigating the first issue, we analyzed the distribution of F-
tests of model fit for the 5 MDS prediction models, as well as
summarizing the individual drug coefficients, multiple correlations
and number of significant models adjusting for multiple testing
[30,31]. To address the second issue, we compared differences in
multiple correlations and number of significant models between
full models (containing both self-reported ethnicity and MDS
dimensions) and nested reduced models excluding either self-
reported-ethnicity or MDS dimensions. These comparisons
describe the marginal contribution of the MDS variables and
self-reported ethnicity, respectively. To formally test the statistical
significance of these marginal effects, we conducted F-tests of
model fit between the full and reduced models. In addition to
summarizing the number and proportion of models in which the
MDS dimension had significant explanatory power over and
above self-reported ethnicity, we also performed Chi-squared tests
of proportions to determine if the number of significant marginal
effects for the MDS variables was more than expected by chance.
For comparison, the statistical significance of self-reported
ethnicity marginal effects was likewise analyzed.
Finally, after establishing the value of GWAS-based ancestral
dimensions as predictors of psychiatric drug response, we then
empirically demonstrate that much smaller sets of markers can be
used to capture this ancestral information. This exercise serves as
proof of concept that such an approach could be applied in clinical
settings using small, inexpensive genotype arrays. Further, we
provide our empirically determined SNP lists and the weights used
to calculate these proxy MDS dimensions in Supporting Infor-
mation S2, as a resource for researchers interested in replicating
these findings or extending efforts to develop predictive algorithms
of psychiatric drug response.
Results
Predictive Power of Genotype-based Ancestry
Figure 1 summarizes results of the regression analyses to test the
null hypothesis that the five ancestral dimensions do not predict
drug response (i.e., observed association is due to statistical noise
and not true signal) using a Quantile-Quantile (QQ) plot for each
of the drug-outcome combinations. The ordered, observed model
fit F-test p-values are plotted against those expected under the null
hypothesis of no true associations among the 136 (CATIE) or 89
(STAR*D) tests, represented by the straight line. The QQ plots
show that the observed p-values deviated systematically from this
straight line and were well outside the 95% confidence intervals.
This provides strong evidence that the five ancestral dimensions
systematically and significantly predicted efficacy and adverse
reaction across these psychiatric pharmacotherapies.
To more exactly quantify the degree to which the ancestral
dimensions predicted drug response, we calculated the ratio of the
median observed test statistic to the expected test statistic under
the null hypothesis. This ratio is commonly used in GWAS as a
measure of the degree to which associations are due to population
differences, and is denoted as lambda (l) [16,32]. In the current
context, l .1 suggests that the ancestral differences captured by
the MDS dimensions do, in fact, influence psychiatric treatment
response. Lambda values were calculated as 1.67 and 1.84 for
CATIE and STAR*D, respectively. Thus, the median of model fit
test statistics was 1.67 and 1.84 times higher than expected under
the null hypothesis for CATIE and STAR*D, respectively. One-
sample Wilcoxon signed rank tests of the median (CATIE: V-
statistic = 3323, p-value ,0.01; STAR*D: V-statistic = 1097, p-
value ,0.001) confirmed that these test statistics were systemat-
ically larger, and p-values smaller, than expected by chance.
A summary of the predictive power of the ancestral dimensions
on individual drug-outcome combinations shows that ancestry
explained a nontrivial portion of variance in both drug efficacy
and side effect outcomes across all treatment regimens (Table 2).
The mean (multiple regression) correlation coefficient was 0.19 in
CATIE and 0.20 in STAR*D, suggesting the 5 dimensions
explained on average about 3.7% and 4.0% of the variation in
antipsychotic and antidepressant response, respectively.
Genotype-based Ancestry and Self-reported Ethnicity
To further study the derived MDS dimensions, we present the
correlations of the five MDS dimensions with self-reported
ethnicity (European American, African American and Hispanic)
in Supporting Information S1. Results showed that MDS 1
generally captured ancestral differences related to European and
African American ancestry, while MDS 2 and 3 seemed to capture
differences between Hispanic v. non-Hispanics groups in CATIE
and STAR*D. The interpretation of the other MDS dimensions
was more ambiguous–they not strongly related to self-reported
ethnicity, suggesting that they capture more subtle (cryptic)
dimensions of population structure [33].
In Table 3 we show results from multiple regression analyses
comparing the predictive power of our ancestral dimensions versus
self-reported ethnicity. In order to compare models, we start with a
fullmodel#1 that includes all 5MDSdimensions plus the 3 ethnicity
variables. Model #2 includes the 5 MDS dimensions only.
Compared to the full model#1, dropping the 3 Ethnicity variables
decreased the correlations on average by 0.046. Even when
controlling the FDR [30] at the 0.95 level, meaning that 95% of the
significant results are expected to be false discoveries, this decrease
was not significant for any of the 137 tested drug-outcome
combinations.Conversely, dropping the5MDSdimensions reduced
the correlations on average by 0.085 where for a number of tested
drug outcome combinations revealed the decrease was significant at
FDR levels of 0.5 and 0.95. Thus, these results suggest that the
marginal explanatory power of the MDS dimensions was generally
greater than self-reported ancestry. The final model # 4, including
the 3 MDS and 3 ethnicity variables, was used to test whether the 2
MDS dimensions that did not correlated strongly with self-reported
Pharmacogenomics and Ancestral Background
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ethnicity (Supporting Information S1) did contribute to the
predicting of drug response. Dropping these 2 MDS dimensions
resulted in anaveragedecrease in correlations of 0.030,with 3, 7, and
25 tests being significant at FDR levels of 0.1, 0.5, and 0.95. Thus,
rather than being technical artifacts, these 2 MDS dimensions
appeared to capture meaningful ancestral differences that did
contribute to the prediction of drug response.
While the results presented in Table 3 describe a systematic
trend of substantial marginal effects for the MDS dimensions, over
and above the effects of self-reported ethnicity, they do not provide
formal statistical tests of these marginal effects. Thus, in table 4 we
present results from F-tests of model fit quantifying the statistical
significance of the marginal effects of the unique MDS dimensions,
over and above the effects of self-report ethnicity. These results
show that for CATIE, 8.1% of models showed a significant
(p,0.05) improvement to model fit with the inclusion of these
MDS variables. A Chi-squared test of proportions indicated that
this 0.081 proportion was significantly greater than the 0.05
proportion expected under the null (x2 statistic = 2.731; x2 p-
value = 0.049). For STAR*D, results for the MDS dimensions
were even stronger with 10.2% of models showing significant
improvement to model fit with the inclusion of the MDS variables.
A Chi-squared test of proportions indicated that this 0.102
proportion was significantly greater than the 0.05 expected under
the null (x2 statistic = 5.062; x2 p-value = 0.012).
For comparison purposes, we applied the same approach to test
the marginal effects of self-reported ethnicity, over and above the
effects of the MDS ancestral dimensions. The proportions of
significant marginal effects for self-reported ethnicity were smaller
than those for the MDS dimensions in both samples. Chi-squared
test of proportions for the self-reported ethnicity marginal effects
showed mixed evidence, with no significant difference from the
null expectation in CATIE (x2 statistic = 1.214; x2 p-value= 0.865)
and a modestly significant result in STAR*D (x2 statistic = 3.100;
x2 p-value = 0.039). In sum, these results demonstrate that the
MDS dimensions explained significant amounts of outcome
variance, over and above that explained by self-reported ethnicity,
in both samples. Further, there is some modest evidence that self-
reported ethnicity may also provide some unique predictive power,
beyond that capture by genotype-based ancestry, for antidepres-
sant drug response.
Finally, as proof of concept that genotype-based ancestry
could potentially be applied in clinical settings, for each of the 5
ancestry dimension, we identified 700 SNPs jointly capturing
approximately the same information as the genome-wide MDS
measures. To do this we proceeded via the following steps.
First, we pruned the genotype data to include only markers in
linkage equilibrium (pairwise R2,0.1) using PLINK’s ‘‘indep’’
function [15]. Next, for each dimension, we sorted the absolute
MDS loadings for the pruned genotype data and selected 700
SNPs with the strongest loadings. Finally, while the loadings
themselves could be used as weights to calculate proxy MDS
scores, to optimize performance of the scores we regressed each
MDS dimension on its 700 top SNPs (using a single multiple
regression model) and used the resulting coefficients as weights
in calculating proxy MDS scores. For all samples and MDS
dimensions, the 700 SNP proxy model explained .99% of
variance in the MDS dimension. Thus, the proxy dimensions
were virtually identical to genome-wide MDS dimensions, and
accordingly, provided equivalent results when substituted in the
primary analysis. In Supporting Information S2, we provide
these empirically determined SNP lists and the weights used to
calculate proxy dimensions as a resource for researchers
interested in replicating these findings or extending efforts
toward developing predictive algorithms of psychiatric drug
response.
Figure 1. Quantile-quantile (Q-Q) plots for the joint effects of MDS dimensions on various drug response measures. Points represent
ordered model fit F-test -log10(p-values), each of which quantifies the explanatory power of a model of 5 MDS ancestral dimensions predicting a
measure of treatment response. The straight, dark grey lines represent the expected p-value distribution under the null hypothesis of no true
associations. Light grey lines represent 95% confidence intervals for rejecting the null hypothesis at each p-value rank. The inflation parameter,
lambda, is defined as the ratio of the median observed test statistic to the expected median under the null distribution; thus, lambda quantifies the
degree to which the test statistic distribution systematically diverges from the null expectation of no significant effects.
doi:10.1371/journal.pone.0055239.g001
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Discussion
Genome-wide estimates of each patient’s unique mosaic of
ancestral backgrounds mediated the effects of all studied antipsy-
chotic and antidepressant drugs on a wide range of efficacy and
toxicity outcomes. This evidence is convincing not only as a result
of the remarkably pervasive associations seen in Figure 1, but also
because of the quality and size of the psychiatric clinical trial
samples analyzed.
One potential explanation of why these effects are so pervasive
is that ancestral differences typically involve a large number of
genetic variants. For instance, over 400,000 markers were
significantly associated with the first MDS dimension in the
CATIE sample. Because the allele frequencies of so many variants
contribute to each ancestral dimension, there are likely to be
Table 2. Summary of the average multiple regression correlation coefficients for the treatment-outcome combinations.
Study/Treatment Phenotype
CATIE
PANSS
total
PANSS
positive
PANSS
negative
Neuro-
cognitive
Body mass
index
Total
cholesterol QTc prolongation Heart rate
Perphenazine 0.174 0.172 0.193 0.283 0.093 0.073 0.094 0.145
Clozapine 0.206 0.174 0.236 0.229 0.429 0.352 0.422 0.346
Olanzapine 0.102 0.131 0.116 0.127 0.202 0.147 0.142 0.134
Quetiapine 0.161 0.168 0.107 0.238 0.293 0.151 0.159 0.207
Risperidone 0.136 0.081 0.101 0.242 0.114 – 0.078 0.031
Ziprasidone 0.180 0.197 0.142 0.213 0.131 0.141 0.100 0.068
STAR*D QIDS Self-
report
QIDS
Clinician
Depressed
affect
Insomnia Appetite/
Weight
Dizziness Sex Eyes/Ears
Citalopram 0.126 0.119 0.120 0.062 0.052 0.099 0.031 0.036
Bupropion 0.205 0.158 0.192 0.221 0.180 0.163 0.121 0.164
Citalopram+Bupropion 0.290 0.304 0.302 0.210 0.138 0.194 0.175 0.210
Citalopram+Buspirone 0.156 0.231 0.200 0.191 0.186 0.173 0.072 0.206
Mirtazapine 0.306 0.233 0.334 0.353 0.364 0.334 0.206 0.274
Nortriptyline 0.280 0.337 0.280 0.229 0.417 0.321 0.141 0.305
Sertraline 0.274 0.240 0.272 0.074 0.131 0.173 0.144 0.200
Venlafaxine 0.176 0.125 0.157 0.228 0.227 0.141 0.145 0.185
PANSS – Positive and Negative Syndrome Scale. QTc - QT interval corrected for heart rate. QIDS – Quick Inventory of Depressive Symptomatology.
doi:10.1371/journal.pone.0055239.t002
Table 3. Multiple regressions analyses predicting antipsychotic and antidepressant treatment response and side-effects using
ancestral background.
Model CATIE STAR*D
Multiple correlation # significant results Multiple correlation # significant results
Mean 1st Qu 3rd Qu q,0.10 q,0.50 q,0.95 Mean 1st Qu 3rd Qu q,0.10 q,0.50 q,0.95
1 5 MDS +3 Ethnicity 0.239 0.174 0.291 1 11 114 0.248 0.186 0.305 4 16 85
2 5 MDS 0.193 0.131 0.246 6 44 116 0.201 0.143 0.243 4 13 86
3 3 Ethnicity 0.154 0.091 0.187 2 40 120 0.158 0.101 0.203 10 26 81
4 3 MDS +3 Ethnicity 0.209 0.136 0.254 2 24 112 0.212 0.152 0.271 7 17 82
Model comparison D multiple correlations D # significant results D multiple correlations D # significant results
Mean 1st Qu 3rd Qu q,0.10 q,0.50 q,0.95 Mean 1st Qu 3rd Qu q,0.10 q,0.50 q,0.95
2 vs. 1 Drop 3 Ethnicity 20.046 20.061 20.016 0 0 0 20.047 20.067 20.017 0 8 13
3 vs. 1 Drop 5 MDS 20.085 20.114 20.046 0 2 40 20.089 20.123 20.046 0 0 72
4 vs. 1 Drop 2 MDS 20.030 20.043 20.007 3 7 25 20.036 20.047 20.009 0 0 87
MDS – multidimensional scaling. Qu – quartile.
In the model comparison section, reductions in the multiple correlations or number of significant results indicate that the compared model had less predictive power
than model #1.
doi:10.1371/journal.pone.0055239.t003
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different subsets of variants that are relevant to response for any
given drug. According to this logic, even though the specific
variants comprising the relevant subset for any given drug-
outcome combination may be unknown, the pervasive genetic
differences captured by the ancestral dimensions are still likely to
have general prognostic value in predicting treatment response.
Consequently, it can be expected that the proposed method will
generalize to a wide variety of other drug-treatment response
combinations.
Our results provide compelling evidence that ancestral infor-
mation powerfully predicts a range of antidepressant and
antipsychotic treatment outcomes. However, establishing that
ancestry influences drug response gives rise to the question: Is
there added value in genotype-based ancestral dimensions over
and above that provided by self-reported ethnicity, which is less
expensive and easier to measure. The results of the current study
suggest that, yes–there is indeed additional value in genotype-
based ancestry. As shown in Table 4, the marginal effects of
unique genotype-based ancestral dimensions provide significant
predictive power over and above self-report ancestry in both the
CATIE and STAR*D studies.
There are several likely reasons for this phenomenon. First,
genetic ancestry is a mosaic of many dimensions that cannot be
captured with a discrete variable comprising few categories.
Indeed, our analyses indicated that while some MDS dimen-
sions corresponded to self-reported ethnicity, others appeared to
capture population differences not measured in conventional
race/ethnicity questionnaires. In addition to being more
nuanced and exhaustive measures of ancestral background,
there are statistical advantages of using quantitative ancestral
dimensions. First, the reduction of statistical power when using
categorical versus quantitative variables is a well-established
phenomenon [34,35]. For example, dichotomizing a predictor at
its median reduces variance explained in a normally distributed
outcome by 38%, with further reductions as the dichotomiza-
tion point moves away from the median [34]. Another
advantage of using a quantitative measure of ancestry in the
prediction algorithm is the possibility to study the full ancestry
spectrum leading to an extension of personalized medicine to
groups that are less represented or have been historically
understudied. For example, due to low sample sizes, minority
racial/ethnic groups are often dropped from analyses to avoid
estimation problems. However, by assessing their unique
ancestral make-up using quantitative dimensions, they can more
readily be included in analyses. None of this is to say, however,
that self-reported ethnicity is without value in the study of drug
response. While the predictive power of self-reported ethnicity
did not match that of genotype-based ancestral dimensions; as
shown in row 3 of Table 3, self-reported ethnicity-only models
did show nontrivial prognostic power in predicting psychiatric
drug response. Further, we observed some tentative evidence (in
STAR*D, but not CATIE) that self-reported ethnicity has
predictive power over and above genotype-based ancestry.
While the tentative nature of this evidence suggests the need
for further study before drawing strong conclusions, if replicat-
ed, this result would be consistent with social constructionist
theories of race arguing that the social categorization of race/
ethnicity has a medical significance independent of genetic
differences [36,37,38]. Such a conclusion would be unsurprising
in light of existing research suggesting ethnically-mediated social
effects on psychiatric treatment response, such as variation in
adherence to antidepressant treatment by English proficiency
between and within ethnic groups [39]. In sum, social categories
measured by self-reported ethnicity may yield additional
information to genetic ancestry, due to capturing social
constructed influences that do not correspond precisely to
genetic ancestry.
While predictive algorithms to personalize psychiatric treat-
ment are still relatively early in development, this research
provides proof of principle that genotype-based ancestry could
easily be incorporated into such future clinical applications. In
this scenario, after collecting genotype data, a pre-existing
algorithm could be used to estimate the ancestral mosaic of new
patients. Ideally, this pre-existing algorithm would be derived
from a large, geographically diverse sample of subjects. Such a
sample would avoid the issue of certain ancestral dimensions
remaining undetected, which would result in reduced predictive
power. Cost of genotyping should not present an obstacle.
Although we had access to over 400,000 polymorphisms, as we
empirically demonstrate above, proxy ancestral dimensions can
be calculated using far fewer genetic markers. Thus, ancestral
dimension scores could be generated using low-end genotyping
arrays currently available for tens of dollars for use in clinical
settings. Clearly, the current effort is only an initial step towards
individualizing treatment and we envision various ways in which
this method may be modified to further increase predictive
power. One shortcoming of the method used here to select and
combine markers into proxy ancestral dimensions is its
susceptibility to overfitting. Thus, future efforts may consider
machine learning methods that explicitly account for overfitting
[40,41]. Further, instead of basing SNP selection on agnostic
genome-wide analyses, the choice of markers could be tailored
to the specific population being studied to obtain more refined
ancestral measures. Such an extension could draw on existing
knowledge of ancestry informative markers (AIMs)
[33,42,43,44], which are specific panels of markers selected to
optimally assess ancestral differences.
The proposed method relies on the premise that a variable need
only be robustly associated with drug response to constitute an
effective predictor. This is clearly inferior to the use of causal
genetic markers that would provide a biological rationale and
facilitate further insight into the pathological process. However,
finding, replicating and validating causal markers predicting
response to a wide variety of drug-indication combinations is apt
to remain a challenging and slow-progressing process for the
Table 4. F-tests of the marginal effects of unique MDS
dimensions and self-reported ethnicity.
CATIE
Model # significant # significant/all x2 statistic x2 p-value
MDS 11 0.081 2.731 0.049
Ethnicity 4 0.029 1.214 0.865
STAR*D
Model # significant # significant/all x2 statistic x2 p-value
MDS 9 0.102 5.062 0.012
Ethnicity 8 0.091 3.100 0.039
MDS – multidimensional scaling.
For both samples, in more models than expected by chance the marginal effect
of the MDS dimensions significantly improved model fit, over and above self-
reported ethnicity. Self-reported ethnicity showed mixed statistical evidence of
improving model fit conditional on the MDS dimensions.
doi:10.1371/journal.pone.0055239.t004
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foreseeable future. Reasons for this include, for instance, the fact
that clinical trials are often unique, with modest sample sizes due
to the enormous cost of conducting these studies. This makes it
difficult to replicate findings in independent samples or to detect
markers with small effects due to insufficient statistical power. In
the meantime, the proposed method may serve as a potent,
immediate starting point for developing algorithms predicting the
most effective and least toxic medication for a wide variety of drug-
indication combinations. As relatively few new psychiatric drugs
are currently under development, such personalized medicine
offers a promising, currently feasible approach toward optimizing
pharmacotherapy for psychiatric conditions.
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